Pipeline

We have a broad and differentiated pipeline of investigational drugs across our family of companies.

Cellular Background

12

positive Phase 3 trials since 2019

We have run numerous large successful international Phase 3 clinical trials.

Agnostic to therapeutic area and modality

Our pipeline includes innovative product candidates across numerous therapeutic areas.

Small Molecule · Priovant
Brepocitinib
Dermatomyositis
Approved
Lisraya logo

LISRAYA (brepocitinib) was approved by FDA for treatment of adults with dermatomyositis in August 2026.

Small Molecule · Priovant
Brepocitinib
Non-Infectious Uveitis
Registrational
Small Molecule · Priovant
Brepocitinib
Cutaneous Sarcoidosis
Registrational
Small Molecule · Priovant
Brepocitinib
Lichen Planopilaris
Registrational
Biologic · Immunovant
IMVT-1402
Graves' Disease
Registrational
Biologic · Immunovant
IMVT-1402
Difficult-to-Treat Rheumatoid Arthritis
Registrational
Biologic · Immunovant
IMVT-1402
Myasthenia Gravis
Registrational
Biologic · Immunovant
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Registrational
Biologic · Immunovant
IMVT-1402
Sjögren’s Disease
Registrational
Biologic · Immunovant
IMVT-1402
Cutaneous Lupus Erythematosus
Proof of Concept
Inhaled · Pulmovant
Mosliciguat
Pulmonary Hypertension associated with Interstitial Lung Disease
Proof of Concept
video section decoration

2026 JP Morgan Healthcare Conference Presentation